Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NXTC 
NextCure Inc (NXTC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: NXTC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $17.5
1 Year Target Price $17.5
| 0 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -57.27% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 13.73M USD | Price to earnings Ratio - | 1Y Target Price 17.5 |
Price to earnings Ratio - | 1Y Target Price 17.5 | ||
Volume (30-day avg) 2 | Beta 1.26 | 52 Weeks Range 2.69 - 19.20 | Updated Date 08/28/2025 |
52 Weeks Range 2.69 - 19.20 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -25.97 |
Earnings Date
Report Date 2025-07-31 | When - | Estimate -0.425 | Actual -11.29 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -53.12% | Return on Equity (TTM) -105.88% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -16632565 | Price to Sales(TTM) 9.52 |
Enterprise Value -16632565 | Price to Sales(TTM) 9.52 | ||
Enterprise Value to Revenue 1.62 | Enterprise Value to EBITDA 0.51 | Shares Outstanding 2676110 | Shares Floating 1878843 |
Shares Outstanding 2676110 | Shares Floating 1878843 | ||
Percent Insiders 14.79 | Percent Institutions 32.58 |
Upturn AI SWOT
NextCure Inc
Company Overview
History and Background
NextCure, Inc. is a biopharmaceutical company focused on discovering and developing immunomedicines to treat cancer and other immune-related diseases. Founded in 2015, it is based on research from Dr. Lieping Chen, and has focused on novel immunotherapy targets.
Core Business Areas
- Drug Development: The company's primary focus is the research, development, and clinical trials of novel immunotherapies for cancer. They identify and validate new immuno-oncology targets.
- Proprietary Platform: NextCure uses its FIND-IO platform to discover and validate novel targets. This is a key aspect of their business model.
Leadership and Structure
The leadership team includes a Chief Executive Officer, Chief Medical Officer, and other key executives. The organizational structure is typical of a clinical-stage biopharmaceutical company, with departments focused on research, development, clinical operations, and finance.
Top Products and Market Share
Key Offerings
- NC410: NC410 is a LAIR-1 antagonist antibody currently in clinical development for solid tumors. There is no current market share yet, as it is in clinical trials. Competitors would be other companies developing novel immunotherapies for solid tumors. Clinical trial data and regulatory approvals will determine success.
- NC762: NC762 is a B7-H4 antagonist antibody currently in preclinical development. There is no market share at this stage. Competitors would be other companies that target the B7-H4 pathway.
Market Dynamics
Industry Overview
The immunotherapy market is a rapidly growing segment of the pharmaceutical industry. Cancer immunotherapy, especially checkpoint inhibitors, has revolutionized cancer treatment. The industry is competitive and dynamic.
Positioning
NextCure is positioned as an innovative player in the immunotherapy field, focusing on discovering and developing novel targets beyond traditional checkpoint inhibitors. Their competitive advantage lies in their proprietary FIND-IO platform.
Total Addressable Market (TAM)
The total addressable market for cancer immunotherapy is estimated to be hundreds of billions of dollars. NextCure is positioned to capture a portion of this TAM by developing successful therapies for various cancers.
Upturn SWOT Analysis
Strengths
- Proprietary FIND-IO platform for target discovery
- Experienced leadership team
- Strong scientific foundation based on Dr. Chen's research
- Focus on novel immunotherapy targets
Weaknesses
- Early-stage clinical development, high risk
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on successful clinical trial outcomes
- Negative operating profit.
Opportunities
- Potential for breakthrough therapies in cancer
- Partnerships with larger pharmaceutical companies
- Expansion of the FIND-IO platform to other immune-related diseases
- Securing regulatory approvals for their drug candidates.
Threats
- Clinical trial failures
- Competition from other immunotherapy developers
- Regulatory hurdles
- Patent challenges
- Financial risks associated with drug development
Competitors and Market Share
Key Competitors
- BMY
- MRK
- PFE
Competitive Landscape
NextCure faces competition from established pharmaceutical companies developing immunotherapies. Their advantage is the FIND-IO platform, and the disadvantage is that they are a smaller company with less resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is based on stock performance, research progress, and partnerships. As a pre-revenue company, traditional revenue growth metrics don't apply.
Future Projections: Future growth depends on the successful development and commercialization of their drug candidates. Analyst estimates depend on data from ongoing clinical trials.
Recent Initiatives: Recent initiatives typically include initiating or progressing clinical trials for NC410 and advancing preclinical programs.
Summary
NextCure is a high-risk, high-reward biopharmaceutical company with innovative immuno-oncology targets. Its strength lies in its discovery platform and pipeline, but weaknesses include its early-stage development and limited resources. It needs to secure partnerships and positive clinical trial data. It should watch out for clinical trial failures and competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings
- Company website
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data and market conditions can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NextCure Inc
Exchange NASDAQ | Headquaters Beltsville, MD, United States | ||
IPO Launch date 2019-05-09 | Co-Founder, CEO, President & Director Mr. Michael S. Richman MSBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 43 | Website https://www.nextcure.com |
Full time employees 43 | Website https://www.nextcure.com | ||
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.